G6PD and breast cancer: Meanwhile, the PYGL and G6PD levels in the primary tumors, including breast cancer, lung adenocarcinoma, and colon cancer, were positively correlated with poor patient survival (Figure 7, B and C, and Supplemental Figure 8, B and C).